IPO, M&A, And SPAC — 3 Life Science Execs Recount Going Public

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

Had I said biotech IPOs were hot last year, it could be construed as one of the biggest understatements of all time, as 2020 biotech IPOs shattered all records. Further, the trend seems to be continuing for 2021. Taking a company public may not be every entrepreneur’s dream, but it is for many life sciences companies, as large amounts of capital remain necessary to bring new therapeutics to market. And as 2020 seems to have forever changed how IPOs (and going public) are done, it seems like there is a great opportunity to capture some wisdom from those who have been there, done that.